## Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Paolo Strati, ${ }^{1}$ Mohamed Amin Ahmed, ${ }^{1}$ Nathan H. Fowler, ${ }^{1}$ Loretta J. Nastoupil, ${ }^{1}$ Felipe Samaniego, ${ }^{1}$ Luis E. Fayad, ${ }^{1}$ Fredrick B. Hagemeister, ${ }^{1}$ Jorge E. Romaguera, ${ }^{1}$ Alma Rodriguez, ${ }^{1}$ Michael Wang, ${ }^{1}$ Jason R. Westin, ${ }^{1}$ Chan Cheah, ${ }^{1}$ Mansoor Noorani, ${ }^{1}$ Lei Feng, ${ }^{2}$ Richard E. Davis ${ }^{1}$ and Sattva S. Neelapu ${ }^{1}$
${ }^{1}$ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center and ${ }^{2}$ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.230649
Received: June 28, 2019.
Accepted: October 4, 2019.
Pre-published: October 10, 2019.
Correspondence: SATTVA S. NEELAPU - sneelapu@mdanderson.org

## Supplementary Data

Pre-Treatment Maximum Standardized Uptake Value Predicts Outcome after Frontline Therapy in Patients with Advanced Stage Follicular Lymphoma

## Strati et al.

Supplementary Table. Analysis of multiple single unit increments of SUV max and PFS in 346 patients included in the study. A starting threshold of 13 was selected, based on historical association between SUV max and risk of transformation. No significant association between SUV $_{\max }$ thresholds and PFS could be observed when limiting the analysis to the 294 patients with $S U V_{\max }<18$

| SUV ${ }_{\text {max }}$ | Patients $(\mathrm{N}=346)$ | Events | Median PFS (months) | HR [95\% CI] | $p$-value |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{array}{r} <=13 \\ >13 \end{array}$ | $\begin{aligned} & 224 \\ & 122 \\ & \hline \end{aligned}$ | $\begin{aligned} & 85 \\ & 44 \\ & \hline \end{aligned}$ | Not reached Not reached | 1 [0.73-1.5] | 0.82 |
| $\begin{array}{r} <=14 \\ >14 \end{array}$ | $\begin{aligned} & 240 \\ & 106 \end{aligned}$ | $\begin{aligned} & 90 \\ & 39 \end{aligned}$ | $145$ <br> Not reached | 1 [0.71-1.5] | 0.85 |
| $\begin{array}{r} <=15 \\ >15 \end{array}$ | $\begin{gathered} 250 \\ 96 \end{gathered}$ | $\begin{aligned} & 94 \\ & 35 \end{aligned}$ | 145 <br> Not reached | 1 [0.69-1.5] | 0.91 |
| $\begin{array}{r} <=16 \\ >16 \end{array}$ | $\begin{gathered} 270 \\ 76 \end{gathered}$ | $\begin{gathered} 100 \\ 29 \end{gathered}$ | Not reached Not reached | 1.1 [0.74-1.7] | 0.61 |
| $\begin{array}{r} <=17 \\ >17 \end{array}$ | $\begin{gathered} 283 \\ 63 \end{gathered}$ | $\begin{gathered} 104 \\ 25 \end{gathered}$ | Not reached 114 | 1.2 [0.80-1.9] | 0.34 |
| $\begin{array}{r} <=18 \\ >18 \end{array}$ | $\begin{gathered} 294 \\ 52 \end{gathered}$ | $\begin{gathered} 106 \\ 23 \\ \hline \end{gathered}$ | Not reached 114 | 1.5 [0.95-2.3] | 0.08 |
| $\begin{array}{r} <=19 \\ >19 \end{array}$ | $\begin{gathered} 302 \\ 44 \end{gathered}$ | $\begin{gathered} 111 \\ 18 \end{gathered}$ | Not reached 114 | 1.3 [0.79-2.2] | 0.29 |
| $\begin{array}{r} <=20 \\ >20 \end{array}$ | $\begin{gathered} 305 \\ 41 \end{gathered}$ | $\begin{gathered} 112 \\ 17 \end{gathered}$ | Not reached 114 | 1.4 [0.82-2.3] | 0.23 |

